We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Bc6.0
BCAAs Research
Probably helps
241 peer-reviewed studies
What the evidence says
Probably helps
BCAAs helped in about half (8/16) of the studies that measured an effect — promising, but not unanimous.
Most evidence is from high-quality meta-analyses and randomised trials published 1979–2026 with a typical study size of 84 participants.
Based on 241 studies · 37 meta-analyses · 166 RCTs · 25,811 total participants
Confidence
High confidence
What the studies found
8helped6unclear2didn't help· 225 more without graded effect data
By outcome
Therapeutic & clinical
Likely helps76 studies
Lean body mass & muscle growthMuscle protein synthesis support · Immediate to 2 hours
Probably helps37 studies
RecoveryReduced muscle soreness · 24-48 hours
Mostly mechanism / observational35 studies
Muscle strength & powerMuscle protein synthesis support · Immediate to 2 hours
Mostly mechanism / observational11 studies
Glucose & metabolic
Mostly mechanism / observational10 studies
Energy & fatigueReduces central fatigue during prolonged exercise · During exercise
Mostly mechanism / observational8 studies
Endurance & exercise performanceReduced mental fatigue during exercise · During exercise · Modest reduction in central fatigue during endurance work · Ongoing
Mostly mechanism / observational7 studies
Heart & blood pressure
Mostly mechanism / observational7 studies
Safety profile
Mostly mechanism / observational4 studies
Liver health
Too few graded studies1 study
By the numbers
Pulled from 40 studies with measurable effects
Likely real effects
63%
across studies
People studied
26k
typical study: 84 people
Strongest designs
203
37 pooled, 166 randomised
Showed benefit
50%
8/16 studies
How long studies ran
1–3 months
1
3+ months
4
Populations Studied
General population5
Exercise participants2
Cirrhotic patients1
Old patients with sarcopenia1
Active research area
94 studies in the last 5 years · Latest meta-analysis: 2026
197920022026
1Event-free survival in cirrhotic patientsMeta-AnalysisCited 21×n=2,308 · very large study2023
Prophylactic BCAA supplementation appears safe and might improve survival in cirrhotic patients.
van Dijk AM et al. · European journal of clinical investigation (2023)
Large benefit
← WorseNo effectBetter →
Likely real
According to meta-analyses, long-term (at least 6 months) BCAA supplementation in cirrhotic patients significantly improved event-free survival (p = .008; RR .61 95% CI .42-.88) and tended to improve overall survival (p = .05; RR .58 95% CI .34-1.00).
Prophylactic BCAA supplementation appears safe and might improve survival in cirrhotic patients.
2Sarcopenia treatment and mitochondrial functionSystematic ReviewCited 27×n=1,337 · large study2023
PROSPERO CRD42022332288.
Cochet C et al. · Nutrients (2023)
Mitochondrial function was significantly improved by the administration of BCAA alone (1 RCT) or in association with vitamin D (1 RCT).
BCAA alone (2 RCTs) or PUFA (1 RCT) were not effective in improving muscle health.
In conclusion, BCAA in association with vitamin D may be useful in the treatment of sarcopenia and boost mitochondrial bioenergetic and redox activity.
4Cardiovascular disease riskMeta-AnalysisCited 30×n=2,806 · very large study2022
Evidence suggests that elevated concentrations of circulating Isoleucine were associated with increased risks of CVD, independent of traditional risk factors.
Wang Y et al. · Atherosclerosis (2022)
Noticeable harm
← WorseNo effectBetter →
Nine prospective studies were meta-analyzed and highlighted a 10% higher risk of CVD per study-specific SD difference for Isoleucine (pooled relative risk 1.10 [1.03-1.18]; I2 = 63.5%).
Evidence suggests that elevated concentrations of circulating Isoleucine were associated with increased risks of CVD, independent of traditional risk factors.
5Type 2 diabetes riskMeta-AnalysisCited 732×n=8,000 · very large study2016
In studies using high-throughput metabolomics, several blood amino acids appear to be consistently associated with the risk of developing type 2 diabetes.
Guasch-Ferré M et al. · Diabetes care (2016)
Noticeable benefit
← WorseNo effectBetter →
Glycine and glutamine were inversely associated with type 2 diabetes risk (0.89 [0.81-0.96] and 0.85 [0.82-0.89], respectively; both I(2) = 0.0%).
In studies using high-throughput metabolomics, several blood amino acids appear to be consistently associated with the risk of developing type 2 diabetes.
6Peripheral fatigue and hormone responsesMeta-Analysisn=146 · medium study2024
The advantages of BCAA administration relate to a reduction in cortisol concentration after 2h and ameliorated muscle function because of a probable attenuation of fatigue substances immediately after exercise.
Pourgharib Shahi MH et al. · Minerva endocrinology (2024)
The advantages of BCAA administration relate to a reduction in cortisol concentration after 2h and ameliorated muscle function because of a probable attenuation of fatigue substances immediately after exercise.
7Seizure activitySystematic ReviewCited 16×n=2,045 · very large study2019
The contradictory effects of BCAAs on seizure activity likely reflect differences in the complex mechanisms that underlie seizure disorders.
Gruenbaum SE et al. · CNS drugs (2019)
The contradictory effects of BCAAs on seizure activity likely reflect differences in the complex mechanisms that underlie seizure disorders.
Some of these mechanisms are likely mediated by BCAA's effects on glucose, glutamate, glutamine, and ammonia metabolism, activation of the mechanistic target of rapamycin signaling pathway, and their effects on aromatic amino acid transport and neurotransmitter synthesis.
We propose that a better understanding of mechanisms by which BCAAs affect seizures and neuronal viability is needed to advance the field of BCAA supplementation in epilepsy.